TSX:BLU

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of chronic cough and other hypersensitization disorders. More Details


Snowflake Analysis

Flawless balance sheet with limited growth.

Share Price & News

How has BELLUS Health's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: BLU has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

4.5%

BLU

-7.7%

CA Biotechs

-0.4%

CA Market


1 Year Return

-64.7%

BLU

55.7%

CA Biotechs

-3.9%

CA Market

Return vs Industry: BLU underperformed the Canadian Biotechs industry which returned 63.5% over the past year.

Return vs Market: BLU underperformed the Canadian Market which returned -4.3% over the past year.


Shareholder returns

BLUIndustryMarket
7 Day4.5%-7.7%-0.4%
30 Day12.8%-7.2%3.1%
90 Day-3.5%10.2%2.4%
1 Year-64.7%-64.7%55.7%55.7%-0.4%-3.9%
3 Year106.4%106.4%14.9%14.9%6.7%-3.8%
5 Year10.8%10.8%-16.7%-16.7%35.5%14.7%

Price Volatility Vs. Market

How volatile is BELLUS Health's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is BELLUS Health undervalued compared to its fair value and its price relative to the market?

1.25x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate BLU's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate BLU's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: BLU is unprofitable, so we can't compare its PE Ratio to the XN Biotechs industry average.

PE vs Market: BLU is unprofitable, so we can't compare its PE Ratio to the Canadian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate BLU's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: BLU is good value based on its PB Ratio (1.3x) compared to the CA Biotechs industry average (5.6x).


Next Steps

Future Growth

How is BELLUS Health forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

-19.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: BLU is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: BLU is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: BLU is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: BLU's revenue (108.1% per year) is forecast to grow faster than the Canadian market (5.8% per year).

High Growth Revenue: BLU's revenue (108.1% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: BLU is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has BELLUS Health performed over the past 5 years?

-76.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: BLU is currently unprofitable.

Growing Profit Margin: BLU is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: BLU is unprofitable, and losses have increased over the past 5 years at a rate of 76% per year.

Accelerating Growth: Unable to compare BLU's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BLU is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-3.2%).


Return on Equity

High ROE: BLU has a negative Return on Equity (-28.61%), as it is currently unprofitable.


Next Steps

Financial Health

How is BELLUS Health's financial position?


Financial Position Analysis

Short Term Liabilities: BLU's short term assets ($76.9M) exceed its short term liabilities ($7.1M).

Long Term Liabilities: BLU's short term assets ($76.9M) exceed its long term liabilities ($9.0K).


Debt to Equity History and Analysis

Debt Level: BLU is debt free.

Reducing Debt: BLU had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: BLU has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: BLU has sufficient cash runway for 1 years if free cash flow continues to reduce at historical rates of 46.3% each year.


Next Steps

Dividend

What is BELLUS Health current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate BLU's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate BLU's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if BLU's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BLU's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of BLU's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

10.2yrs

Average management tenure


CEO

Roberto Bellini (40 yo)

10.75yrs

Tenure

US$2,225,553

Compensation

Mr. Roberto Bellini has been the Chief Executive Officer and President of BELLUS Health Inc, since January 1, 2010. Mr. Bellini served as an Executive Vice President of Picchio Pharma Inc. until January 1, ...


CEO Compensation Analysis

Compensation vs Market: Roberto's total compensation ($USD1.31M) is above average for companies of similar size in the Canadian market ($USD623.14K).

Compensation vs Earnings: Roberto's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Roberto Bellini
President10.75yrsUS$2.23m0.83%
$ 2.1m
François Desjardins
Vice President of Finance11.25yrsUS$584.78k0.011%
$ 28.2k
Denis Garceau
Senior Vice President of Drug Development15.75yrsUS$834.13k0.00089%
$ 2.3k
Catherine Bonuccelli
Chief Medical Officer1.17yrsUS$3.52mno data
Tony Matzouranis
Vice President of Business Development8.67yrsUS$617.21kno data
Daniel Matthews
Director of Investor Relations & Communicationsno datano datano data
Sébastien Roy
Corporate Secretary9.67yrsno data0.0021%
$ 5.5k

10.2yrs

Average Tenure

52yo

Average Age

Experienced Management: BLU's management team is seasoned and experienced (10.2 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Roberto Bellini
President10.75yrsUS$2.23m0.83%
$ 2.1m
Francesco Bellini
Chairman of the Boardno dataUS$458.48k0.56%
$ 1.4m
Franklin Berger
Independent Director10.42yrsUS$156.74k0.69%
$ 1.8m
Joseph Rus
Independent Director11.75yrsUS$169.24kno data
Clarissa Desjardins
Independent Director3.08yrsUS$149.24k0.024%
$ 62.5k
Youssef Bennani
Independent Director3.42yrsUS$156.74k0.14%
$ 371.8k
Pierre Larochelle
Independent Lead Directorno dataUS$201.74k0.17%
$ 446.2k
Alan Goldsobel
Member of Clinical Advisory Board2.08yrsno datano data
Jacky Smith
Chairman of the Clinical Advisory Board2.08yrsno datano data
Lorcan McGarvey
Member of Clinical Advisory Board2.08yrsno datano data
Alyn Morice
Member of Clinical Advisory Board2.08yrsno datano data
Mandel Sher
Member of Clinical Advisory Board2.08yrsno datano data

2.6yrs

Average Tenure

59yo

Average Age

Experienced Board: BLU's board of directors are not considered experienced ( 2.6 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: BLU insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 36.9%.


Top Shareholders

Company Information

BELLUS Health Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: BELLUS Health Inc.
  • Ticker: BLU
  • Exchange: TSX
  • Founded: 1993
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: CA$257.730m
  • Shares outstanding: 78.34m
  • Website: https://www.bellushealth.com

Number of Employees


Location

  • BELLUS Health Inc.
  • 275 Armand-Frappier Boulevard
  • Laval
  • Quebec
  • H7V 4A7
  • Canada

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BHN0DB (Deutsche Boerse AG)YesCommon SharesDEEURJun 2000
BLUNasdaqGS (Nasdaq Global Select)YesCommon SharesUSUSDJun 2000
BLUTSX (The Toronto Stock Exchange)YesCommon SharesCACADJun 2000
0UL1LSE (London Stock Exchange)YesCommon SharesGBCADJun 2000

Biography

BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of chronic cough and other hypersensitization disorders. Its lead drug candidate includes BLU-5937, a ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/23 23:38
End of Day Share Price2020/10/23 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.